Serum pyruvate and lactate predict immunotherapy efficacy in advanced gastric cancer: a prospective biomarker study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Serum lactate and pyruvate levels can predict immunotherapy effectiveness in advanced gastric cancer patients. Lower levels indicate better outcomes, offering a non-invasive biomarker for treatment guidance.
Area Of Science
- Oncology
- Biochemistry
- Immunotherapy
Background
- Immunotherapy has transformed advanced gastric cancer treatment.
- Predicting treatment efficacy remains a challenge.
- Non-invasive circulating biomarkers are needed for monitoring.
Purpose Of The Study
- To investigate serum energy metabolites as predictors of chemoimmunotherapy efficacy.
- To explore the role of glycolysis and TCA cycle metabolites in immune evasion and treatment response.
Main Methods
- Prospective observational study of 52 advanced gastric cancer patients.
- Quantification of serum glycolysis and TCA cycle metabolites using LC-MS/MS.
- Evaluation of therapeutic response, progression-free survival (PFS), and overall survival (OS).
Main Results
- Decreased serum lactate and pyruvate correlated with higher disease control rates.
- Elevated lactate and pyruvate were linked to inferior PFS and OS.
- Low lactate and pyruvate identified as independent prognostic factors for improved survival.
Conclusions
- Serum lactate and pyruvate are promising non-invasive biomarkers for predicting immunotherapy efficacy in gastric cancer.
- Further validation in larger cohorts is necessary to guide clinical decisions.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.